Metrics as of 10/13/2026, 06:31 PM (Berlin time), refresh in progress.
Medicenna Therapeutics Stock
Medicenna Therapeutics Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Fahar Merchant
- Employees
- 15
- Market cap
- $35 M
- IPO
- 08/03/2017
Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) empowered cytokine, has successfully finished Phase IIb trials for recurrent…
Medicenna Therapeutics stock: price history
1D
+2.3%
1W
+3.4%
1M
+12.5%
6M
-26.2%
YTD
-51.1%
1Y
-49.4%
2Y
-80.3%
5Y
-84.9%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~27% stronger price swings than usual
Ask the agents about Medicenna Therapeutics
Analyst assessment of Medicenna Therapeutics
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 06/12/2024
Medicenna Therapeutics stock metrics
P/E
-1.97
P/B
22.53
EV/EBITDA
-1.23
RETURN ON EQUITY
-303.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.4%
FLOAT SHARES
62,410,363
AVG. DAILY VOLUME (30D)
40,280
Comparable stocks
Frequently asked questions about Medicenna Therapeutics stock
What does Medicenna Therapeutics do?
Medicenna Therapeutics Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Fahar Merchant, the company employs around 15 people.
The IPO was on 08/03/2017; the stock trades on TSX under the ticker MDNA.TO.
What do analysts say about Medicenna Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 06/12/2024).
This is an external assessment, not a statement by Market Jury.
When does Medicenna Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 27% stronger than usual.
Does Medicenna Therapeutics pay a dividend?
No, Medicenna Therapeutics currently does not pay a dividend.
Which stocks are comparable to Medicenna Therapeutics?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Medicenna Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Medicenna Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.